Trial Profile

A Phase 2 Clinical Trial to Evaluate SB 11285 for the Treatment of Selected Cancers

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 05 Oct 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs SB 11285 (Primary)
Indications Cancer; Solid tumours
Focus Therapeutic Use
Sponsors F-star Therapeutics; Spring Bank Pharmaceuticals

Most Recent Events

03 Feb 2020 New trial record
29 Jan 2020 According to a Spring Bank Pharmaceuticals media release, by the end of 2020, the company plans to generate sufficient data from the Phase 1a/1b IV STING agonist program to enable advancement into this phase 2 clinical trial.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com